255 related articles for article (PubMed ID: 31874999)
1. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.
Coilly A; Desterke C; Guettier C; Samuel D; Chiappini F
Sci Rep; 2019 Dec; 9(1):19785. PubMed ID: 31874999
[TBL] [Abstract][Full Text] [Related]
2. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH).
Wagner J; Kumar Y; Lautenbach A; von Kroge P; Wolter S; Mann O; Izbicki J; Gagliani N; Duprée A
Lipids Health Dis; 2023 Jan; 22(1):1. PubMed ID: 36609276
[TBL] [Abstract][Full Text] [Related]
5. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
[TBL] [Abstract][Full Text] [Related]
7. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
8. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
Loomba R; Quehenberger O; Armando A; Dennis EA
J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
Kado A; Tsutsumi T; Enooku K; Fujinaga H; Ikeuchi K; Okushin K; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
[TBL] [Abstract][Full Text] [Related]
10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
11. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
De A; Duseja A
J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
13. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.
Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A
J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
Voiculescu M; Nanau RM; Neuman MG
J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
[TBL] [Abstract][Full Text] [Related]
17. [An Overview of NAFLD/NASH in Japan].
Kim SR; Kim KI
Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
19. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
[TBL] [Abstract][Full Text] [Related]
20. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]